M&A Deal Summary

US WorldMeds Acquires Solstice Neurosciences

On August 13, 2010, US WorldMeds acquired life science company Solstice Neurosciences for 36M USD

Acquisition Highlights
  • This is US WorldMeds’ 1st transaction in the Life Science sector.
  • This is US WorldMeds’ largest (disclosed) transaction.
  • This is US WorldMeds’ 1st transaction in the United States.
  • This is US WorldMeds’ 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2010-08-13
Target Solstice Neurosciences
Sector Life Science
Buyer(s) US WorldMeds
Deal Type Add-on Acquisition
Deal Value 36M USD
Advisor(s) MTS Health Partners LP (Financial)

Target

Solstice Neurosciences

Malvern, Pennsylvania, United States
Solstice Neurosciences is a specialty biopharmaceutical company headquartered in Malvern, PA with a production and manufacturing facility in San Francisco.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

US WorldMeds

Louisville, Kentucky, United States
Category Company
Founded 2001
Sector Life Science
DESCRIPTION

US WorldMeds is a Kentucky-based specialty pharmaceutical company that develops, licenses and commercializes unique medical therapies that address unmet patient needs. US WorldMeds’ products include novel treatments for malignant hyperthermia, cervical dystonia and symptoms of opiate withdrawal.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2010) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-09 US WorldMeds - CNS Portfolio

Kentucky, United States

US WorldMeds LLC - CNS Portfolio (central nervous system) is involved in developing and commercializing products for the treatment of Parkinson’s disease.

Sell -
Mergr

Product

Company

Legal